Peak is a Phase 3 clinical trial evaluating bezuclastinib (CGT9486), a selective and potent KIT inhibitor, in combination with sunitinib, in people with locally advanced, unresectable, or metastatic Gastrointestinal Stromal Tumors (GIST) who have previously received imatinib.
You may be eligible if you:
- Are 18 years of age or older
- Have histologically confirmed locally advanced, metastatic and/or unresectable GIST
- Have received prior therapy with imatinib
You are not eligible if you:
- Have a known PDGFR⍺ D842V mutation or known SDH deficiency
- Are pregnant or breastfeeding
To find out if you are eligible for this clinical trial, you should talk to your doctor.
The Peak clinical trial is expected to be conducted at investigative sites across approximately 20 countries. Please check back soon for more information on specific clinical trial sites.
Have Questions about the Peak Clinical Trial?Below are some frequently asked questions about the Peak clinical trial:
If you or someone you know are interested in the Peak clinical trial for GIST, please feel free to share this email.
Cogent Biosciences, Inc. is a biotechnology company developing real solutions to treat genetically driven diseases. With a focus on the design of rational precision therapies, we are leveraging validated biology to address the true underlying drivers of disease and provide real hope for patients.
Millions of people around the world are living with a genetically defined disease. Mutations can create a ripple effect in the body to trigger illness – cancers, autoimmune conditions, and rare diseases. For most of these diseases, despite the available therapies, there still exists a significant unmet need to extend survival and improve the quality of life for patients.
Explore our website to find out more.